View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 7, 2021updated 12 Jul 2022 11:20am

Oxford-AstraZeneca paediatric vaccine trial halted amid blood clot concerns

A trial of the Oxford-AstraZeneca Covid-19 vaccine in children and teens has been put on hold while the UK’s drug regulator investigates a possible link between the jab and rare blood clots in adults.

By Kezia Parkins

A trial of the Oxford-AstraZeneca Covid-19 vaccine in children and teens has been put on hold while the UK’s drug regulator investigates a possible link between the jab and rare blood clots in adults.

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

The University of Oxford has halted the paediatric trials of its vaccine, developed in collaboration with pharma giant AstraZeneca, after the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) launched a probe into the potential connection with the jab.

In a statement, the university said it has not seen any safety issues from the trial itself, but decided to pause the study because of concerns about rare blood clotting problems reported in multiple countries.

The trial organisers are awaiting more information from the MHRA, which is currently undergoing a “serious and detailed review” of the shot.

“Whilst there are no safety concerns in the paediatric clinical trial, we await additional information from the MHRA on its review of rare cases of thrombosis/thrombocytopenia that have been reported in adults, before giving any further vaccinations in the trial,” the university said. “Parents and children should continue to attend all scheduled visits and can contact the trial sites if they have any questions.”

Paediatric trials of the Oxford-AstraZeneca jab commenced in over 200 children aged from six to 17 years in February.

In March, the vaccine was reported as safe and effective by both the World Health Organization and the European Medicines Agency, which saw a number of European member states resume vaccinations with the AZ jab, after temporarily pausing their rollout efforts.

Last week the UK government revealed there had been 30 severe blood clotting cases reported out of 15.8 million administered doses of the AstraZeneca vaccine, leading to seven deaths.

The MHRA stated that no similar rare blood-clotting cases were seen among those injected with the Pfizer-BioNTech vaccine.

In an interview with Italian newspaper Il Messaggero, EMA head of vaccine strategy Marco Cavaleri said it was “clear there is a link with the vaccine” and the clotting cases but that there was still uncertainty about what exactly was causing such a reaction.

He also stressed that the vaccine’s benefits outweigh its potential risks.

Cavaleri said that among younger vaccinated people there was a higher-than-expected number of cases of cerebral thrombosis – blood clotting in the brain – compared with the general population.

France, Germany, Italy, Spain, the Netherlands and Canada have all suspended the dosing of AstraZeneca in people under 55, 60 or 65.

UK Prime Minister Boris Johnson has continued to recommend the the Oxford-AZ vaccine, advising the population “to keep going out there, get your jab, get your second jab”.

In an interview with The Independent, University of Reading associate professor in cellular microbiology Dr Simon Clarke said the UK could “afford to be cautious” in suspending the trial of the Oxford-AstraZeneca vaccine in children, because it has access to other options.

The UK has just bought 17 million doses of the Moderna jab, which has been found to be 100% effective against severe Covid-19 cases in Phase III trials. A 24-year-old woman received the first dose of the jab in the UK today.

In a news conference discussing the blood-clotting concerns of the Oxford-AstraZeneca vaccine, the MHRA announced that citizens aged between 18-29 will be offered an alternative Covid-19 jab where possible.

Related Companies

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena